| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01270347 | Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients | PHASE3 | COMPLETED | 282 | — | — | Jan 1, 2011 | Jun 1, 2013 | Dec 13, 2024 | 130 | United States, France +4 |
| NCT00840333 | "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" | PHASE1 | COMPLETED | 27 | — | — | Apr 1, 2009 | Dec 1, 2009 | Dec 4, 2024 | 6 | United States |
| NCT00503490 | Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis | PHASE1 | COMPLETED | 40 | — | — | Jun 1, 2007 | Dec 1, 2007 | Dec 4, 2024 | 14 | United States |
An AE was defined as any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a Study Drug, whether or not considered related to the Study Drug. An AE could potentially be a new disease, any untoward event, or an exacerbation of a pre-existing condition. AEs included, but were not limited to: Any symptom not previously reported by the patient (medical history) An exacerbation of a pre-existing illness An increase in frequency or intensity of a pre-existing episodic event or condition A condition first detected or diagnosed after Study Drug administration even though the condition may have been present before the start of the study Overdose of Study Drug
FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer. Least squares (LS) mean and standard error (SE) were determined from an analysis of covariance model with terms for treatment, region (US, non-US), and age (12 to 18 years, \> 18 years), and Baseline FEV1 (\< 55%, . 55%).
| Arm | Type | Description |
|---|---|---|
| Aeroquin | EXPERIMENTAL | Aeroquin, Inhaled Levofloxacin (MP-376) |
| TIS | ACTIVE_COMPARATOR | Tobramycin Inhalation solution (TIS) \[TOBI® Novartis Pharmaceuticals\] |
| 1 | EXPERIMENTAL | CF PATIENTS 6-11 YEARS OF AGE |
| 2 | EXPERIMENTAL | CF PATIENTS 12-16 YEARS OF AGE |
| Name | Type | Description |
|---|---|---|
| MP-376 (Levofloxacin Solution for Inhalation) | DRUG | MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment |
| TIS (Tobramycin Inhalation Solution) | DRUG | Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment |
| placebo | DRUG | BID |
Inclusion Criteria (selected): * \> 12 years of age * Confirmed Diagnosis of Cystic Fibrosis * Positive sputum culture for P. aeruginosa within the past 12 months * Patients are able to elicit an FEV1 \>/= 25% but \</= 85% of predicted value at screening * Have received at least 3 courses of inhale...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 9 | PHASE3 | VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, VNZ/TEZ/D-IVA, VX-522 mRNA therapy |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719, SION-451, SION-2222, SION-109 |
| BiomX Ltd | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | — | Undisclosed |